Titan Medical Signs Licensing Agreement with Auris Health
By Robb M. Stewart
Canadian medical technology company Titan Medical entered a licensing agreement with Johnson & Johnson's Auris Health business covering certain intellectual property.
Titan under the agreement granted Auris a non-exclusive license to a portion of its intellectual property.
The Toronto-based company, which developed a patent portfolio related to the enhancement of robotic-assisted surgery, earlier this year transitioned to an IP licensing company in an effort to generate revenue from licensing existing patents. The move saw Titan terminate research and development and it signed two licensing agreements with two companies in the surgical robotic industry for total upfront payments of $15.5 million.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
August 21, 2023 08:04 ET (12:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis